Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 12/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12542153 | 0.91 | ICMT (0.63) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL12541340 | 0.90 | OPRM1 (0.77) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL12692092 | 0.89 | ICMT (0.73) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL18886901 | 0.88 | OPRM1 (0.65) | ICMTOPRM1HTR1AHTR7HTR6 | |
| SCHEMBL13546105 | 0.88 | ALDH1A1 (0.64) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL14542602 | 0.86 | HTR1A (0.69) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL31731143 | 0.85 | OPRM1 (0.67) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL14542462 | 0.83 | HTR1A (0.71) | ICMTOPRM1MAPK1HTR1AHTR7 | |
| SCHEMBL18886985 | 0.82 | OPRM1 (0.71) | ICMTOPRM1HTR1AHTR7HTR6 | |
| SCHEMBL19614672 | 0.82 | ICMT (0.61) | ICMTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389657-A1 | METHODS OF TREATING HYPERALGESIA | Trevena, Inc. (US) | 2018-10-24 | — | — | EP | claimed |
| WO-2017106306-A1 | METHODS OF TREATING HYPERALGESIA | TREVENA, INC. (US) | 2017-06-22 | — | — | WO | claimed |
| EP-2688403-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | Trevena, Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2012129495-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | WO | claimed |
| US-11931350-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220175747-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175747-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11077098-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210023043-A1 | Methods of Treating Hyperalgesia | TREVENA, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10588889-B2 | Methods of treating hyperalgesia | TREVENA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10588898-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190343819-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20150246904-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2015-09-03 | — | — | US | disclosed |
| US-9044469-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9044469-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129495-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175747-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
| US-20190343819-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
| US-11931350-B2 | Opioid receptor ligands and methods of using and making same | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
| US-10588889-B2 | Methods of treating hyperalgesia | OPRL1, OPRK1, CHAT | ICMT 3127/4885OPRM1 35/4885MAPK1 4150/4885 |
| US-10588898-B2 | Opioid receptor ligands and methods of using and making same | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
| US-11077098-B2 | Opioid receptor ligands and methods of using and making same | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
| US-20210023043-A1 | Methods of Treating Hyperalgesia | OPRL1, OPRK1, CHAT | ICMT 3127/4885OPRM1 35/4885MAPK1 4150/4885 |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
| US-20150246904-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | ICMT 2179/4885OPRM1 3/4885MAPK1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.